Infection with Clostridioides difficile in the context of COVID-19
Keywords:
Clostridium difficile, COVID-19 pandemic, pathogenic flora antibioticsAbstract
This study refers to a group of 110 patients, hospitalized in the IMSP SCBI “Toma Ciorbă”, with the diagnosis of Enterocolitis due to Clostridium difficile in the period March 2020 - June 2023. The purpose of the research: Clinical, laboratory and epidemiological evaluation of cases of CDIs that appeared during the Covid-19 pandemic. The following research methods were applied: documentary; mathematic and statistics. A significant increase in the incidence of ICD was found in the Republic of Moldova during the Covid-19 pandemic period, compared to the pre-pandemic period. The imbalance of the intestinal microbiota, resulting from long-term antibiotic therapy, favors colonization with C. difficile, as well as other pathogenic flora.
References
1. Akerlund T., Persson I., Unemo M. et al. Increased sporulation rate of epidemic Clostridium difficile type 027/ NAP1. In: J. Clin. Microbiol. 46(4), 1530-1533 (2008). https://doi.org/10.1128/JCM.01964-07
2. Brown K. A., Khanafer N., Daneman N. et al. Antibiotics and the risk of community associated Clostridium difficile infection (CDI): a meta-analysis. In: Antimicrob. Agents Chemother. 2013, 57:2326-2332. https://doi.org/10.1128/AAC.02176-12
3. Collins J., Auchtung J. M. Control of clostridium difficile infection by defined microbial communities. Microbiol Spectr. (2017) 5:10.
https://doi.org/10.1128/microbiolspec.BAD-0009-2016
4. Lessa F. C., Mu Y., Bamberg W. M., Beldavs Z. G., Dumyati G. K., Dunn J. R. și colab. Povara infecției cu Clostridium difficile în Statele Unite . N Eng J Med. (2015) 372 :825-34. https://doi.org/10.1056/NEJMoa1408913
5. Lewandowski K., Rosolowski M., Kaniewska M., Kucha P., Meler A., Wierzba W., Rydzewska G. Clostridioides difficile infection in coronavirus disease 2019 (COVID-19): an underestimated problem. Pol. Arch. Intern. Med. 2021;131(2):121-127. https://doi.org/10.20452/pamw.15715
6. Ministerul Sănătății, Muncii și Protecției Sociale al Republicii Moldova, GHID Managementul infecţiei cu Clostridioides difficile, Chișinău 2021
7. Ponce-Alonso M., Saez De La Fuente J., Rincon-Carlavilla A., Moreno-Nunez P., Martinez-Garcia L., Escudero-Sanchaez R. et al. Impactul pandemiei bolii coronavirus 2019 (COVID-19) asupra infecției nosocomiale cu Clostridioides difficile. Infecta. Control Hosp. Epidemiol. 2020:1-5. https://doi.org/10.1017/ice.2020.454
8. Prevalence and Health Outcomes of Clostridioides difficile Infection During the Coronavirus Disease 2019 Pandemic in a National Sample of United States Hospital Systems.
9. Shen A. Clostridium difficile toxins: mediators of inflammation. J Innate Immun. (2012) 4:149-58. https://doi.org/10.1159/000332946
10. Voona S., Abdic H., Montgomery R., Clarkson A., Twitchell H., Hills T., Briggs S., Crooks C., Monaghan T. M. Impact of COVID-19 pandemic on prevalence of Clostridioides difficile infection in a UK tertiary centre. Anaerobe. 2022 Feb;73:102479. Epub 2021 Nov 18. PMID: 34801705; PMCID: PMC8607812. https://doi.org/10.1016/j.anaerobe.2021.102479
11. Wu D., Yang X. O. TH17 responses in cytokine storm of COVID-19: an emerging target of JAK2 inhibitor Fedratinib. J Microbiol Immunol Infect. (2020) 53:368-70. https://doi.org/10.1016/j.jmii.2020.03.005
12. Yu H., Chen K., Sun Y., Carter M., Garey K.W., Savidge T. C. et al. Cytokines are markers of the clostridium difficile-induced inflammatory response and predict disease severity. Clin Vaccine Immunol. (2017) 24:e00037-17. https://doi.org/10.1128/CVI.00037-17
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
